Research in the Seyfried lab is focused on the integration of proteomics, systems biology, and molecular biology to tackle fundamental questions related to the pathogenesis of Alzheimer’s Disease (AD) and other neurodegenerative disorders. In particular, we utilize high resolution liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) to identify and quantify proteins and post-translational modifications (PTMs). Combining tools in both molecular and cellular biology, we also explore the relationship between the function of these proteins and their PTMs in the development of these devastating diseases.
Our funded projects are currently focused on the development of mass spectrometry-based techniques for:
(1) Systems level analysis of quantitative proteomic and transcriptomic expression in human donor postmortem brain tissue
(2) Identification and quantification of protein post-translational modifications including ubiquitination, phosphorylation, methylation and acetylation
(3) Proteomic biomarker discovery in cerebrospinal fluid (CSF), plasma and platelets in Alzheimer’s Disease and other related neurodegenerative diseases
(4) Proteogenomic applications to identify rare coding changes at the peptide level in AD candidate risk genes
In the News
July 2017, Press Release: Our research on Alzheimer’s Disease protein networks was highlighted in an article on Alzforum titled, "Alzheimer’s Proteomics Treasure Trove?"
July 2017, Conference Presentation: Nick co-chaired and presented a talk in the Protein-Protein Interactions Session at the Alzheimer’s Association International Conference (AAIC) in London, England.
July 2017, Paper Accepted: Our paper titled, “Integrating Next-Generation Genomic Sequencing and Mass Spectrometry to Estimate Allele-Specific Protein Abundance in Human Brain,” was accepted for publication to the Journal of Proteome Research. This work was done in collaboration with Thomas Wingo (Emory Neurology), who developed the GenPro software.
June 2017, Nick Presented at talk titled, “Protein co-expression network analysis of asymptomatic Alzheimer’s disease” at the EMBO | EMBL Symposia on Mechanisms in Neurodegeneration in Heidelberg Germany.
March 2017, Conference Presentation: Nick Presented at talk titled, “A Multi-Network Approach to Define Pathways Altered in Alzheimer’s Disease and Parkinson’s Disease” at the US HUPO meeting in San Diego, CA.